COVID-19 Myocarditis: A Basic Researcher’s Perspective
Expert
DeLisa Fairweather, Ph.D.
Date
Sept. 14-16, 2022
Location
Cardioimmunology Zurich 2022 Meeting (Symposium 5: Therapy of Cardiac Inflammation), Kartause Ittingen, Switzerland (in person).
Summary
Dr. Fairweather describes sex differences in COVID from the Expanded Access Program data and the literature, and how that relates to sex differences in myocarditis caused by SARS-CoV-2.
Sex Differences in Mitochondria During Viral Myocarditis and COVID-19 Vaccine-Induced Myocarditis
Expert
DeLisa Fairweather, Ph.D.
Date
June 16-17, 2022
Location
2022 NIH NHLBI Workshop on “Sex-Specific COVID-19 Outcomes and Management Relevant for Heart, Lung and Blood Disorders” (Session 4: Cardiovascular and Aspects of COVID-19: Sex and Gender Considerations), Washington DC (virtual).
Summary
Dr. Fairweather describes sex differences in COVID from the Expanded Access Program data and the literature, and how that relates to sex differences in myocarditis caused by SARS-CoV-2.
Sex Differences in Mortality in COVID-19 Patients Administered Convalescent Plasma
Expert
Katelyn A. Bruno, Ph.D.
Date
May 5, 2022
Location
Organization for the Study of Sex Differences, Annual Meeting, Marina del Rey, California
Summary
Dr. Bruno describes the use of convalescent plasma in history and during the COVID-19 pandemic, outlines the formation and extent of the United States Convalescent Plasma Expanded Access program (EAP), presents some of the results previously published by the EAP team, and shares new results looking at sex differences in mortality in EAP patients.
2022 ASA Florida Chapter Meeting
Expert
Rickey E. Carter, Ph.D.
Date
April 1, 2022
Location
American Statistical Association, Florida Chapter Annual Meeting, Jacksonville, Florida (webinar)
Summary
Dr. Carter presents details on how Mayo Clinic built a team during a pandemic and lessons learned from the United States Convalescent Plasma Expanded Access program.
COVID-19 Therapeutics in 2022: Advances and Controversies in Evidence, Oversight, Accessibility and Utility of Therapy
Experts
DeLisa Fairweather, Ph.D., Michael J. Joyner, M.D. and R. Scott Wright, M.D.
Date
Feb. 26, 2022
Location
Mayo Clinic School of Continuous Professional Development (livestream)
Summary
In this interactive livestream event leading experts from Mayo Clinic, Johns Hopkins and the U.S. Food and Drug Administration will educate and update clinicians, researchers, health care executives and policy makers on the current state of therapeutic options for COVID-19. Livestream recordings.
Convalescent Plasma Ab Levels and Risk of Death from COVID-19
Expert
DeLisa Fairweather, Ph.D.
Date
Oct. 8-9, 2021
Location
CIMCONX: 10th Annual Individualizing Medicine Conference, Ponte Vedra, Florida (virtual)
Summary
Dr. Fairweather presents an overview of the Expanded Access Program with a summary of key outcomes and findings, including information about the efficacy and optimal timing of monoclonal antibody therapies, Remdesivir and convalescent plasma.
From Half Full to Half Empty: How Pandemics Affect the Blood Supply — Fresh Challenges and New Opportunities
Expert
Allan Klompas, M.B., B.Ch., B.A.O.
Date
Oct. 22, 2021
Location
Johns Hopkins Cardiac Anesthesia Visiting Professor Exchange (virtual)
Summary
Dr. Klompas discusses how pandemics affect the allogeneic blood supply and how COVID-19 impacted blood transfusions in the US, including the many challenges it created, and then highlights ways the community turned challenges into opportunities.
US COVID-19 Convalescent Plasma Expanded Access Program (EAP): Creation and Implementation
Expert
Katelyn A. Bruno, Ph.D.
Date
Sept. 15, 2021
Location
Indiana Association of Blood Banks (ISABB) Annual Meeting (virtual)
Summary
Dr. Bruno describes the formation of the EAP and the development of the database used to register sites and physicians, enroll patients, collect events and outcome data, and shows some of the initial results.
Innovations in Regulation & Regulatory Science — what we learned from the COVID-19 pandemic
Experts
Michael J. Joyner, M.D. and DeLisa Fairweather, Ph.D.
Date
August 19, 2021
Location
Mayo Clinic Innovations in Regulatory Science Course (CTSC 5025), Rochester, Minnesota (virtual)
Summary
Drs. Joyner and Fairweather present regulatory hurdles occurring with the Mayo Clinic-led EAP for convalescent plasma for COVID-19; and how innovative solutions were devised in collaboration with the FDA to overcome these issues during a pandemic, which led to successful distribution of convalescent plasma nationwide.
Convalescent Plasma and COVID-19
Expert
Michael J. Joyner, M.D.
Date
August 25, 2021
Location
Duke University Medical Center, Durham, North Carolina (livestream and online)
Summary
Providing access to convalescent plasma during a pandemic was a remarkable logistic and humanitarian effort. Learn how Mayo Clinic adopted and led the EAP.
Sex Differences and COVID-19
Expert
Michael J. Joyner, M.D.
Date
June 11, 2021
Location
Transforming Women’s Health CME Courses, Rochester, Minnesota (livestream and online)
Summary
Dr. Joyner describes the basic epidemiology of COVID-19 in the US, summarizes the main risk factors for poor outcomes and assesses the role biological sex plays as a risk factor.
COVID-19 Plasma Biostatistics Team
Expert
Rickey E. Carter, Ph.D.
Date
May 20, 2021
Location
Mayo Clinic Applied Statistics Seminar 2021 Series, Jacksonville, Florida (webinar)
Summary
Dr. Carter and team provide an overall description of the EAP project and the role Mayo Clinic biostatisticians played in making this project a huge success.
Update on the Use of Convalescent Plasma for COVID-19
Expert
DeLisa Fairweather, Ph.D.
Date
April 23, 2021
Location
Baptist Heart & Vascular Institute Cardiovascular Symposium (virtual)
Summary
This update covers the history of using convalescent plasma and the expanded access program (EAP), key findings of the EAP, where convalescent plasma transfusion stands today, and effects on cardiovascular disease.
The Expanded Access Program (EAP) for COVID-19
Expert
DeLisa Fairweather, Ph.D.
Date
Feb. 27, 2021
Location
International Society of Cardiomyopathy, Myocarditis and Heart Failure: Kyoto, Japan (livestream)
Summary
Dr. Fairweather discusses COVID-19 clinical trials investigating the cardiac-related complications of COVID-19.
The US Convalescent Plasma Program and Mayo Clinic
Experts
R. Scott Wright, M.D., Michael J. Joyner, M.D., DeLisa Fairweather, Ph.D., and Rickey E. Carter, Ph.D.
Date
Feb. 24, 2021
Location
Mayo Clinic Medical Grand Rounds (livestream)
Summary
Providing access to convalescent plasma during a pandemic was a remarkable logistic and humanitarian effort. Learn how Mayo Clinic adopted and led the EAP.
US COVID-19 Convalescent Plasma Expanded Access Program (EAP): Creation and Implementation
Expert
Katelyn A. Bruno, Ph.D.
Date
Feb. 12, 2021
Location
Children's Health Transfusion and Laboratory Medicine annual conference (virtual)
Summary
Dr. Bruno describes the formation of the EAP and the development of the database used to register sites and physicians, enroll patients, collect events and outcome data, and show some of the initial results.
State of Pandemic Preparedness That Has Characterized the US Over the Past Year
Expert
Michael J. Joyner, M.D.
Date
Feb. 12, 2021
Location
Arizona State University honors course (virtual)
Summary
COVID-19 has underscored several truths about pandemics and revealed important shortcomings in current global and national capacities to prepare for, detect and respond to them. To better prepare for the next crisis, and future waves of the current one, the United States will need to devote considerable political capital and economic resources to reducing the domestic and global vulnerabilities that jeopardize individual, national and global health security.
2020 Report Card on Expanded Access to COVID-19 Therapeutics, Vaccines and Diagnostics
Expert
Michael J. Joyner, M.D.
Date
Feb. 11, 2021
Location
Ax-S Pharma (virtual)
Summary
Learn about the experience of coordinating the largest EAP in history: the 2020 treatment-use trial for COVID-19 convalescent plasma, which treated over 105,000 people. Scalable EAPs need to be easy for both the health care provider and the provider's institution.
Delivery System Reform Options — Redesigning the Practice
Expert
Michael J. Joyner, M.D.
Date
Feb. 5, 2021
Location
Arizona State University (webinar)
Summary
Delivery system reform options could support participating hospitals' programs to enhance access to care, the quality of care, and the health of the patients and families they serve.
Relationship Between Antibody Titers and Death in COVID-19 Patients
Expert
Michael J. Joyner, M.D.
Date
Jan. 29, 2021
Location
University of Kansas (virtual)
Summary
Patients receiving the plasma with low antibody levels had the highest mortality rate. Mortality for those receiving the medium-level antibody convalescent plasma was lower, and high antibody convalescent plasma showed the lowest mortality rate.
US Convalescent Plasma Program — Insights and Observations
Expert
R. Scott Wright, M.D.
Date
Jan. 19, 2021
Location
Richard Doll Virtual Seminar Series: University of Oxford, U.K. (livestream)
Summary
What is convalescent plasma and the history of its use in medicine? Learn how a multidisciplinary team responded to a request from the Food and Drug Administration to rapidly develop an expanded access program to collect and distribute convalescent plasma for the treatment of COVID-19.
Providing Expanded Access to Convalescent Plasma During a Pandemic
Expert
DeLisa Fairweather, Ph.D.
Date
Jan. 15, 2021
Location
Mayo Clinic Grand Rounds: Jacksonville, Florida (livestream)
Summary
Dr. Fairweather describes Mayo Clinic's charge from the Food and Drug Administration, the Biomedical Advanced Research and Development Authority, and the cohort that joined the expanded access program (EAP).
Providing Expanded Access to Convalescent Plasma During a Pandemic
Expert
DeLisa Fairweather, Ph.D.
Date
Jan. 11, 2021
Location
University of Puerto Rico School of Medicine: San Juan, Puerto Rico (livestream)
Summary
Dr. Fairweather describes Mayo Clinic's charge from the Food and Drug Administration, the Biomedical Advanced Research and Development Authority, and the cohort that joined the EAP.
Challenges in Health Disparities Research
Expert
Michael J. Joyner, M.D.
Date
Jan. 11, 2021
Location
University of Puerto Rico faculty research program (virtual)
Summary
Dr. Joyner discusses challenges in discovering, addressing and resolving health disparities in COVID-19 research. During the EAP, the recruitment of a diverse population improved over the course of the study.
Convalescent Plasma: What We Have Learned From COVID-19
Expert
Michael J. Joyner, M.D.
Date
Jan. 9, 2021
Location
University of Toronto (St. George Campus) Research Symposium — COVID-19: Investigating a Viral Phenomenon(virtual)
Summary
Convalescent plasma gave hope to patients and physicians at a time when there was little more available for treating people with COVID-19 than supportive therapy. The patients treated under the EAP were geographically and ethnically diverse. The EAP created access to the therapy for many patients in the United States who would not otherwise have had access to clinical trials.
Expanded Access Program (EAP) for Convalescent Plasma
Expert
Michael J. Joyner, M.D.
Date
Dec. 17, 2020
Location
Mayo Clinic Research Gathering: Rochester, Minnesota (virtual)
Summary
The EAP mobilized and launched nationally in days. Hear what we've learned about the urgency needed in pandemic response.
COVID-19 Podcast Update
Expert
Michael J. Joyner, M.D.
Date
Nov. 13, 2020
Location
Mayo Clinic Anesthesiology & Perioperative Medicine podcast, episode 17 (podcast)
Summary
Dr. Joyner provides an update on convalescent plasma and emergency use authorization as well as the status of vaccinations.
Weathering a Pandemic: COVID-19 and Research Activities at Mayo Clinic
Expert
Rickey E. Carter, Ph.D.
Date
Nov. 10, 2020
Location
Florida Department of Health Grand Rounds: Jacksonville, Florida (webinar)
Summary
Dr. Carter describes the structure of the EAP both in terms of the study objectives and implementation characteristics and provides insights on how the EAP directly reached residents of Florida.
The Convalescent Plasma EAP: From Concept to Execution
Expert
DeLisa Fairweather, Ph.D.
Date
Nov. 10, 2020
Location
Florida Department of Health Grand Rounds: Jacksonville, Florida (livestream)
Summary
This presentation provides an overview of how a multidisciplinary team responded to a request from the Food and Drug Administration to rapidly develop an expanded access program to collect and distribute convalescent plasma for the treatment of COVID-19.
Perspectives of Real-World Data From Expanded Access During COVID-19
Expert
Michael J. Joyner, M.D.
Date
Oct. 9, 2020
Location
New York University-University of Arizona (webinar)
Summary
By analyzing trends in COVID-19 data sets, the research community helped rapidly fill in knowledge gaps around disease symptoms, risk factors, racial disparities and more. Such observational methods also hinted at which treatments seemed to be making an impact — and which were not — all in near real time.
COVID-19 and Bioethics
Experts
DeLisa Fairweather, Ph.D., Michael J. Joyner, M.D., and R. Scott Wright, M.D.
Date
Oct. 2, 2020
Location
Mayo Clinic School of Continuous Professional Development (livestream)
Summary
Learn about the impact of the coronavirus pandemic on the health care system through specific examination of the effects on the workforce, research and the regulatory environment, vaccines, potential cures, and epidemiologic tracking. The Mayo Clinic experience and adaptive response to the pandemic are highlighted.
How the Urgency of the Public Health Emergency Meant We Had To Do Things Differently
Expert
DeLisa Fairweather, Ph.D.
Date
Sept. 23, 2020
Location
Mayo Clinic Innovation Forum: Jacksonville, Florida (livestream)
Summary
Learn how science can help the world recover from a pandemic.
Update on Safety and Efficacy of COVID-19 Convalescent Plasma 2
Expert
DeLisa Fairweather, Ph.D.
Date
Sept. 16, 2020
Location
The Biosafety Level 4 Zoonotic Laboratory Network (BSL4ZNet) COVID-19 Research Symposium Miniseries: Ottawa, Canada (webinar)
Summary
Dr. Fairweather discusses enhancing scientific knowledge and global capacity for preparedness for current and future high-consequence pathogen needs.
Treatment of COVID-19
Expert
Michael J. Joyner, M.D.
Date
Sept. 15, 2020
Location
American Society of Gene & Cell Therapy (virtual)
Summary
Dr. Joyner presents on the potential use of convalescent plasma in both preventive and treatment applications.
US COVID-19 Convalescent Plasma Expanded Access Program (EAP)
Expert
Katelyn A. Bruno, Ph.D.
Date
Sept. 1, 2020
Location
REDCap Public Health Workgroup (virtual)
Summary
Dr. Bruno describes the use of REDCap for the COVID-19 EAP. She discusses each version of the database along with lessons learned.
Convalescent Plasma and COVID-19
Expert
Michael J. Joyner, M.D.
Date
Aug. 25, 2020
Location
Duke University Department of Anesthesiology Grand Rounds (virtual)
Summary
Dr. Joyner covers what was learned through a study that analyzed the safety of convalescent plasma transfusion in patients who were hospitalized with COVID-19 and received the drug through the expanded access program (EAP) for COVID-19.
Convalescent Plasma: COVID-19 Livestream
Experts
Katelyn A. Bruno, Ph.D., DeLisa Fairweather, Ph.D., Michael J. Joyner, M.D., Jonathan (Jack) Senefeld, Ph.D., and R. Scott Wright, M.D.
Date
Aug. 1, 2020
Location
Mayo Clinic School of Continuous Professional Development (livestream)
Summary
Find information on the treatment of hospitalized patients with severe or life-threatening COVID-19. Topics covered include the history and evolution of convalescent plasma therapies; implementation of the EAP for patients with COVID-19; current data; blood bank and donor recruitment strategies; and world perspectives on treatment patients with COVID-19 with plasma.
How the Urgency of the Public Health Emergency Meant We Had To Do Things Differently
Expert
DeLisa Fairweather, Ph.D.
Date
July 23, 2020
Location
Mayo Clinic Innovation Forum: Jacksonville, Florida (livestream)
Summary
How science can help the world recover from a pandemic.
COVID-19: The US Convalescent Plasma Story
Experts
Michael J. Joyner, M.D., and R. Scott Wright, M.D.
Date
July 20, 2020
Location
Mayo Clinic Cardiovascular Grand Rounds (livestream)
Summary
Learn about what convalescent plasma is, the historical background of convalescent plasma use in infectious disease and use of convalescent plasma in COVID-19.
The Safety of Convalescent Plasma
Expert
Michael J. Joyner, M.D.
Date
May 22, 2020
Location
Mayo Clinic School of Continuous Professional Development; Mayo Clinic Talks COVID-19 Miniseries Episode 31: Rochester, Minnesota (podcast)
Summary
What nuances apply for convalescent plasma's application to treating COVID-19? Dr. Joyner discusses what's known about this treatment option, information currently being gathered and how you can get involved.
COVID-19 Event Update
Expert
Michael J. Joyner, M.D.
Date
May 19, 2020
Location
Mayo Clinic School of Continuous Professional Development (livestream)
Summary
This update covers current research initiatives related to the COVID-19 pandemic, promising innovative solutions for treatment strategies for patients with COVID-19, expedited translational research related to COVID-19 and innovative practice redesign principles to treat patients in a virtual setting.
National COVID-19 Convalescent Plasma Project
Expert
Michael J. Joyner, M.D.
Date
April 27, 2020
Location
Mayo Clinic Anesthesiology and Perioperative Medicine Grand Rounds (podcast)
Summary
What is convalescent plasma and how is it used to treat patients with COVID-19? Dr. Joyner provides an overview of the expanded access program, COVID-19 clinical trials related to convalescent plasma, lessons learned and future directions.